Dr. Comer is interested in the development of infectious disease models that
can be used to evaluate the vaccine and therapeutics under the standards set by
the United States Food and Drug Administration (FDA). Dr. Comer plans and
oversees preclinical studies to ensure they meet the FDA regulations. Dr. Comer
has extensive experience designing and directing Good Laboratory Practice (GLP;
21 CFR Part 58)-compliant studies to test the efficacy of medical
countermeasures to a variety of select agents. His end goal is to facilitate the
FDA licensure of new vaccines and therapeutics to bio-threat agents and newly
emerging diseases.
Search PubMed for Dr. Comer's publications.